Share This Page
Drug Price Trends for NDC 72603-0445
✉ Email this page to a colleague
Average Pharmacy Cost for 72603-0445
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ARIPIPRAZOLE 1 MG/ML SOLUTION | 72603-0445-01 | 0.48805 | ML | 2024-12-18 |
| ARIPIPRAZOLE 1 MG/ML SOLUTION | 72603-0445-01 | 0.46003 | ML | 2024-11-20 |
| ARIPIPRAZOLE 1 MG/ML SOLUTION | 72603-0445-01 | 0.56313 | ML | 2024-11-06 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 72603-0445
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
72603-0445 Market Analysis and Financial Projection
Market Analysis and Price Projections for Drug NDC: 72603-0445
Understanding the NDC Directory
To analyze the market and project prices for a drug with the National Drug Code (NDC) 72603-0445, it is crucial to understand the context provided by the FDA's National Drug Code Directory. The NDC Directory contains detailed information on finished, unfinished, and compounded drug products, including their marketing status and pricing data[1].
Drug Identification
The NDC 72603-0445 corresponds to a specific drug product. However, without the exact drug name in the provided sources, we can infer that it would be listed under the FDA's NDC Directory, which includes all finished drugs, whether prescription or over-the-counter, approved or unapproved, and repackaged or relabeled drugs.
Market Trends in the Pharmaceutical Industry
Pricing and Access Issues
The pharmaceutical industry is currently facing significant challenges related to pricing and access to drugs. C-suite executives in the life sciences sector identify pricing and access as the most critical issues affecting their strategies. Nearly half of the executives surveyed expect these issues to significantly impact their strategies in 2025[3].
Global Price Disparities
The prices of drugs in the U.S. are notably higher compared to other regions. For instance, the average price per unit in the U.S. was 5.5 times higher than in the OECD (excluding the U.S.) and 7.7 times higher than in the rest of the world in 2022. This disparity is partly due to the drug mix in the U.S., which skews towards more expensive compounds[4].
Impact of Medicare Price Negotiation
Recent initiatives, such as the Medicare drug price negotiation program, are aimed at reducing drug costs. For example, the Biden-Harris Administration has negotiated lower prices for the first ten drugs selected for the Medicare program, resulting in savings of up to 79% on some drugs. This trend suggests that regulatory efforts can significantly influence drug pricing[2].
Price Projections
Regulatory Influence
Given the current regulatory environment, especially with the Medicare price negotiation program, there is a likelihood that prices for many drugs, including those with high usage and cost, will be negotiated downward. If the drug with NDC 72603-0445 is among those commonly used by Medicare beneficiaries, it could be subject to similar price negotiations, leading to potential price reductions.
Market Dynamics
The pharmaceutical market is also influenced by competition from generic drugs and biosimilars. As patents expire on high-revenue products, the market is expected to see increased competition, which can drive prices down. For instance, if the drug associated with NDC 72603-0445 faces competition from generics or biosimilars, its price could decrease over time[3].
Technological and Scientific Advancements
Advances in genomics, biomarkers, and personalized medicine are expected to improve treatment efficacy and reduce side effects. While these innovations can lead to more precise and effective treatments, they may also result in higher initial costs. However, as these technologies become more widespread, economies of scale could reduce prices over time[3].
Key Factors Affecting Price
Patent Expiration and Generic Competition
If the drug associated with NDC 72603-0445 is nearing patent expiration, the entry of generic competitors could significantly reduce its price. The biopharma industry is facing a substantial loss of exclusivity, with over $300 billion in sales at risk through 2030 due to expiring patents[3].
Regulatory Changes
Changes in regulatory policies, such as those implemented by the Medicare price negotiation program, can directly impact drug prices. If this drug is included in future negotiation rounds, its price could be significantly reduced[2].
Market Demand and Supply
The demand for the drug, influenced by factors such as disease prevalence and treatment guidelines, will also impact its price. Additionally, supply chain disruptions or manufacturing issues could affect pricing by altering the availability of the drug.
Illustrative Statistics
- The U.S. saw an average price increase of 14% between 2017 and 2022, while prices in the OECD (excluding the U.S.) and the rest of the world decreased by 9% and 7%, respectively[4].
- The Medicare price negotiation program is expected to save Medicare $6 billion if the negotiated prices had been in effect during 2023, and it is projected to save $1.5 billion in out-of-pocket costs for Medicare Part D enrollees in 2026[2].
Expert Insights
"We are full of expectations for personalized medicine," explained a senior vice president of a small German pharma company. "With advances in genomics and biomarkers, we can provide patients with more precise treatment options. This not only improves efficacy but also significantly reduces side-effects, allowing patients to have a better treatment experience."[3]
Conclusion
The market analysis and price projections for the drug with NDC 72603-0445 depend on several factors, including regulatory changes, market competition, technological advancements, and global price disparities. Given the current trends, it is likely that prices for many drugs will be influenced by regulatory negotiations and increased competition from generics and biosimilars.
Key Takeaways
- Regulatory Impact: Initiatives like the Medicare price negotiation program can significantly reduce drug prices.
- Market Competition: Generic and biosimilar competition can drive prices down as patents expire.
- Technological Advancements: Advances in personalized medicine may initially increase costs but could lead to economies of scale over time.
- Global Price Disparities: U.S. drug prices are significantly higher than in other regions, which could influence pricing strategies.
- Market Demand and Supply: Demand and supply dynamics will continue to play a crucial role in determining drug prices.
FAQs
Q: How does the FDA's NDC Directory impact drug pricing?
The FDA's NDC Directory provides comprehensive information on drug products, including their marketing status, which can influence pricing by ensuring transparency and compliance with regulatory requirements.
Q: What is the impact of Medicare price negotiation on drug costs?
The Medicare price negotiation program has resulted in significant price reductions for selected drugs, with savings ranging from 38% to 79%. This program aims to lower drug costs for Medicare beneficiaries.
Q: How do global price disparities affect U.S. drug prices?
U.S. drug prices are notably higher than in other regions. This disparity is partly due to the drug mix in the U.S., which skews towards more expensive compounds, and regulatory differences.
Q: What role do generic and biosimilar drugs play in price projections?
Generic and biosimilar drugs can significantly reduce prices as they enter the market, especially as patents expire on high-revenue products.
Q: How do technological advancements in personalized medicine affect drug pricing?
Advances in personalized medicine can initially increase costs due to the development of more precise and effective treatments. However, as these technologies become more widespread, they could lead to economies of scale and reduced prices over time.
Sources
- FDA's National Drug Code Directory - FDA
- FACT SHEET: Biden-Harris Administration Announces New, Lower Prices for First Ten Drugs Selected for Medicare Price Negotiation - White House
- 2025 life sciences outlook - Deloitte Insights
- ISSUE BRIEF - International Market Size and Prices - ASPE
- METOPROLOL SUCCINATE tablet, extended release - DailyMed
More… ↓
